Furthermore, establishing the clinical relevance of these findings, ara‐C treated AML patients with low SAMHD1 expression have a significantly better overall survival compared to those with high expression [14, 144, 147], clearly highlighting SAMHD1 as a therapeutic target in this context [140]. Here, SAMHD1 is linked to acute myeloid leukemia.